phenoxodiol

Small moleculeexperimental

Clinical trial activity

7 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
4
Phase 3
1
Phase 4
0

Earliest trial started Aug 1, 2001 (NCT00022295)

Timeline

2000s

  1. Jan 1, 2001

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 3 Sponsor(trial)

  3. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Oc1ccc(C2=Cc3ccc(O)cc3OC2)cc1
Mol. weight
240.26 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2h-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)
  • 3-(4-hydroxyphenyl)-2h-chromen-7-ol
  • 3-(4-hydroxyphenyl)-2h-chromen-7-ol
  • 7-hydroxy-3-hydroxyphenyl-1h-benzopyran
  • dehydroequol
  • dehydroequol
  • haginin e
  • haginin e
  • idronoxil
  • idronoxil
  • idronoxil
  • idronoxil
  • nv-06
  • nv-06
  • phenoxodiol
  • phenoxodiol
  • phenoxodiol
  • phenoxodiol

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03041285Phase 1Apr 30, 2017Northern Sydney Local Health District, University of Sydney
NCT02941523Phase 1/Phase 2 (Phase 2)Mar 3, 2017Noxopharm Limited
NCT00557037Phase 2Nov 1, 2007MEI Pharma, Yale University
NCT00382811Phase 3Oct 1, 2006MEI Pharma
NCT00303888Phase 1May 1, 2006National Cancer Institute (NCI), Yale University
NCT00091377Phase 1/Phase 2 (Phase 2)Aug 1, 2004Kazia Therapeutics Limited, MEI Pharma
NCT00022295Phase 1Aug 1, 2001Kazia Therapeutics Limited, MEI Pharma
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MEI PharmaFor profit4332001
Kazia Therapeutics LimitedFor profit2122001
Yale UniversityAcademic/Hospital2122006
National Cancer Institute (NCI)Government1012006
Northern Sydney Local Health DistrictAcademic/Hospital1012017
Noxopharm LimitedFor profit1112017
University of SydneyAcademic/Hospital1112017
7 organizations
Page 1 / 1